Gilead Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Gilead Sciences wird ein jährliches Gewinn- und Umsatzwachstum von 36.2% bzw. 2.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 36.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 34.5% betragen.

Wichtige Informationen

36.2%

Wachstumsrate der Gewinne

36.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.1%
Wachstumsrate der Einnahmen	2.2%
Zukünftige Eigenkapitalrendite	34.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	01 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Apr 22

Gilead Sciences: Some Signs Of An Impending Bottom

Apr 22

Gilead Sciences: Realizing Financial Projections Is Key

Mar 20

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Mar 13

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Mar 01

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Feb 28

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Feb 15

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Feb 13

Gilead Sciences: Cheap For A Reason

Feb 10

Gilead Sciences: The Sky Is Not Falling

Feb 01

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

Jan 15

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Dec 25

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:GILD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	28,743	6,834	10,209	10,079	24
12/31/2025	27,985	6,305	10,000	9,799	27
12/31/2024	27,592	387	8,136	5,978	27
3/31/2024	27,450	485	7,900	8,481	N/A
12/31/2023	27,116	5,665	7,421	8,006	N/A
9/30/2023	27,391	5,876	7,853	8,404	N/A
6/30/2023	27,382	5,484	8,926	9,512	N/A
3/31/2023	27,043	5,583	8,386	8,976	N/A
12/31/2022	27,281	4,592	8,344	9,072	N/A
9/30/2022	27,136	3,334	9,007	9,710	N/A
6/30/2022	27,515	4,137	9,415	10,100	N/A
3/31/2022	27,472	4,515	9,953	10,614	N/A
12/31/2021	27,305	6,225	10,805	11,384	N/A
9/30/2021	27,482	7,394	9,491	10,095	N/A
6/30/2021	26,638	5,162	8,472	9,092	N/A
3/31/2021	25,564	301	8,698	9,342	N/A
12/31/2020	24,689	123	7,518	8,168	N/A
9/30/2020	23,147	1,268	8,160	8,832	N/A
6/30/2020	22,174	-257	8,510	9,227	N/A
3/31/2020	22,716	4,962	8,244	9,003	N/A
12/31/2019	22,449	5,386	8,319	9,144	N/A
9/30/2019	22,365	2,693	8,039	8,909	N/A
6/30/2019	22,357	5,955	7,639	8,476	N/A
3/31/2019	22,320	5,892	6,758	7,707	N/A
12/31/2018	22,127	5,455	7,476	8,400	N/A
9/30/2018	22,281	1,587	7,912	8,808	N/A
6/30/2018	23,197	2,208	8,432	9,290	N/A
3/31/2018	24,690	3,464	10,559	11,243	N/A
12/31/2017	26,107	4,628	N/A	11,898	N/A
9/30/2017	27,478	11,601	N/A	12,684	N/A
6/30/2017	28,466	12,213	N/A	14,383	N/A
3/31/2017	29,101	12,637	N/A	15,842	N/A
12/31/2016	30,390	13,501	N/A	17,047	N/A
9/30/2016	31,576	15,076	N/A	18,382	N/A
6/30/2016	32,371	16,346	N/A	18,085	N/A
3/31/2016	32,839	17,341	N/A	18,758	N/A
12/31/2015	32,639	18,108	N/A	21,250	N/A
9/30/2015	31,447	16,912	N/A	18,476	N/A
6/30/2015	29,194	15,043	N/A	18,424	N/A
3/31/2015	27,485	14,207	N/A	16,951	N/A
12/31/2014	24,890	12,101	N/A	12,818	N/A
9/30/2014	20,696	9,406	N/A	10,524	N/A
6/30/2014	17,437	7,463	N/A	7,233	N/A
3/31/2014	13,669	4,580	N/A	4,001	N/A
12/31/2013	11,202	3,075	N/A	3,105	N/A
9/30/2013	10,585	3,046	N/A	3,084	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GILDDas prognostizierte Gewinnwachstum (36.2% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: GILDDie Erträge des Unternehmens (36.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: GILDEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: GILDDie Einnahmen des Unternehmens (2.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: GILDDie Einnahmen des Unternehmens (2.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GILDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (34.5%)

Gilead Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 79%

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Recent updates

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Records Positive Phase III Results In HIV

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences: Cheap For A Reason

Fourth quarter dividend increased to US$0.77

Full year 2023 earnings: EPS misses analyst expectations

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences: The Sky Is Not Falling

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study